Citius Pharmaceuticals Inc (CTXR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.69M
Last updated: Nov 17, 2026 at 11:00 AM ET
Citius Pharmaceuticals Inc (CTXR) Financials: Revenue, Profit and Cash Flow
Citius Pharmaceuticals reported revenue of $0 for the fiscal year ended Sep 30, 2025. That year, net income was -$39.74M, operating cash flow was -$26.55M and free cash flow was -$26.55M. The quarter ended Jun 30, 2026 had revenue of $1.49M and net income of -$11.92M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of $38.53M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $0 | N/A | N/A | N/A | N/A |
| Sep 2024 | $0 | N/A | N/A | N/A | N/A |
| Sep 2023 | $0 | N/A | N/A | N/A | N/A |
| Sep 2022 | $0 | N/A | N/A | N/A | N/A |
| Sep 2021 | $0 | N/A | N/A | N/A | N/A |
| Sep 2020 | $0 | N/A | N/A | N/A | N/A |
| Sep 2019 | $0 | N/A | N/A | N/A | N/A |
| Sep 2018 | $0 | N/A | N/A | N/A | N/A |
| Sep 2017 | $0 | N/A | N/A | N/A | N/A |
| Sep 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Sep 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $9.16M | $11.91M | $14.82M | $17.66M | $12.24M | $8.81M | $8.60M | $6.56M | $2.94M | $2.93M |
| Operating income | -$38.53M | -$42.00M | -$36.73M | -$33.32M | -$23.53M | -$17.71M | -$15.60M | -$13.79M | -$9.99M | -$7.45M |
| Net income | -$39.74M | -$39.43M | -$32.54M | -$33.64M | -$23.05M | -$17.55M | -$15.56M | -$12.54M | -$10.38M | -$8.30M |
| EBITDA | -$38.31M | -$39.40M | -$36.54M | -$33.14M | -$23.31M | -$17.45M | -$15.60M | -$12.97M | -$9.53M | N/A |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49M | $1.67M | $3.94M | $0 | $0 | $0 | $0 | $155.93K | $0 | $0 | $0 | $0 |
| Gross profit | $1.00M | $1.34M | $3.15M | -$62.04K | $0 | $0 | $0 | -$53.69K | $0 | $0 | $0 | -$49.97K |
| Operating income | -$11.73M | -$32.19M | -$9.02M | -$8.44M | -$8.79M | -$11.26M | -$10.04M | -$11.05M | -$10.63M | -$10.97M | -$9.34M | -$10.12M |
| Net income | -$11.92M | -$28.11M | -$9.39M | -$8.74M | -$9.20M | -$11.51M | -$10.28M | -$11.08M | -$10.57M | -$8.54M | -$9.23M | -$9.94M |
Balance Sheet
As of Sep 2025, cash and equivalents exceeded total debt of $1.00M by $3.25M.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $130.94M | $116.65M | $103.61M | $114.00M | $142.43M | $43.77M | $36.75M | $31.05M | $24.42M | $21.95M |
| Current assets | $27.93M | $14.22M | $34.37M | $44.56M | $72.81M | $13.98M | $7.94M | $10.06M | $3.42M | $892.84K |
| Cash and equivalents | $4.25M | $3.25M | $26.48M | $41.71M | $70.07M | $13.86M | $7.89M | $9.18M | $3.20M | $294.35K |
| Total liabilities | $53.41M | $42.55M | $12.18M | $10.57M | $9.65M | $10.10M | $9.59M | $3.18M | $2.47M | $5.18M |
| Short-term debt | $1.00M | $0 | $436.76K | $393.98K | $354.47K | $172.97K | $172.97K | $172.97K | $172.97K | $672.97K |
| Long-term debt | $0 | N/A | N/A | N/A | N/A | $164.58K | $0 | N/A | N/A | N/A |
| Shareholder equity | $67.55M | $70.08M | $90.83M | $102.83M | $132.18M | $33.67M | $27.15M | $27.87M | $21.95M | $16.77M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $142.26M | $132.54M | $140.39M | $130.94M | $127.68M | $121.48M | $120.70M | $116.65M | $97.09M | $90.71M | $97.40M | $103.61M |
| Total liabilities | $66.35M | $63.46M | $46.92M | $53.41M | $60.12M | $57.91M | $51.78M | $42.55M | $10.81M | $10.74M | $12.07M | $12.18M |
| Cash and equivalents | $17.01M | $4.59M | $7.72M | $4.25M | $6.09M | $26.41K | $1.10M | $3.25M | $17.91M | $12.56M | $20.35M | $26.48M |
| Shareholder equity | $66.61M | $61.54M | $79.96M | $67.55M | $65.06M | $60.66M | $65.41M | $70.08M | $85.68M | $79.37M | $84.73M | $90.83M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Sep 2025.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$26.55M | -$28.20M | -$29.06M | -$28.36M | -$24.25M | -$16.93M | -$12.44M | -$11.32M | -$7.97M | -$5.90M |
| Capital expenditures | $0 | $0 | $2 | $0 | $40.01M | $1.83K | $0 | $0 | $2.13K | $0 |
| Free cash flow | -$26.55M | -$28.20M | -$29.06M | -$28.36M | -$64.26M | -$16.93M | -$12.44M | -$11.32M | -$7.97M | -$5.90M |
| Dividends paid | $0 | $3.83M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$5.75M | -$5.00M | $0 | $0 | -$40.01M | -$1.83K | $0 | $0 | -$2.13K | $255.75K |
| Financing cash flow | $33.30M | $9.97M | $13.83M | $0 | $120.47M | $22.90M | $11.15M | $17.30M | $10.88M | $5.26M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.68M | -$1.30M | -$13.01M | -$11.88M | -$5.41M | -$4.54M | -$4.73M | -$5.91M | -$8.37M | -$7.79M | -$6.14M | -$6.80M |
| Capital expenditures | N/A | $0 | $0 | $4 | $0 | $4 | $0 | $0 | $4 | $0 | $0 | $0 |
| Free cash flow | N/A | -$1.30M | -$13.01M | -$11.88M | -$5.41M | -$4.54M | -$4.73M | -$5.91M | -$8.37M | -$7.79M | -$6.14M | -$6.80M |
Frequently Asked Questions About CTXR
What is Citius Pharmaceuticals' annual revenue?
Citius Pharmaceuticals reported revenue of $0 for the fiscal year ended Sep 30, 2025.
Is Citius Pharmaceuticals profitable?
No. Citius Pharmaceuticals reported net income of -$39.74M for the fiscal year ended Sep 30, 2025.
How much free cash flow does CTXR generate?
For the fiscal year ended Sep 30, 2025, operating cash flow of -$26.55M minus capital expenditures of $0 produced free cash flow of -$26.55M.
How much debt does Citius Pharmaceuticals have?
The balance sheet dated Sep 30, 2025 reported long-term debt of $0, short-term debt of $1.00M and cash and equivalents of $4.25M.
CTXR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors